Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vebreltinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Apollomics Inc
Deal Size : $60.0 million
Deal Type : Agreement
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Details : under the agreement, LaunXP receives exclusive development and commercialization rights for APL-101 (vebreltinib) in combination with an EGFR inhibitor for the treatment of non-small cell lung cancer.
Product Name : APL-101
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
March 31, 2025
Lead Product(s) : Vebreltinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Apollomics Inc
Deal Size : $60.0 million
Deal Type : Agreement